SCHEMBL1129750

SCHEMBL1129750

CC(=O)OC(O[C]=O)c1ccccc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 2/20 0.49
ALDH1A1 P00352 1/20 0.49
PABPC1 P11940 1/20 0.39
APOBEC3A P31941 1/20 0.39
APOBEC3G Q9HC16 1/20 0.39
TSHR P16473 1/20 0.39
KMT2A Q03164 2/20 0.39
HSD17B10 Q99714 1/20 0.38
MEN1 O00255 1/20 0.38
HPGD P15428 1/20 0.37
HCAR2 Q8TDS4 1/20 0.37
CYP2D6 P10635 2/20 0.36
SRC P12931 1/20 0.36
CYP19A1 P11511 2/20 0.36
CYP1A2 P05177 1/20 0.36
PKM P14618 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
NPSR1 Q6W5P4 1/20 0.36
LMNA P02545 2/20 0.35
MAPK1 P28482 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL486678 0.85 ALDH1A1 (0.63) CYP3A4ALDH1A1PABPC1APOBEC3AAPOBEC3G
SCHEMBL14798131 0.83 ALDH1A1 (0.61) CYP3A4ALDH1A1PABPC1APOBEC3AAPOBEC3G
SCHEMBL1030015 0.79 ALDH1A1 (0.53) CYP3A4ALDH1A1PABPC1APOBEC3AAPOBEC3G
SCHEMBL9068581 0.78 ALDH1A1 (0.51) CYP3A4ALDH1A1TSHRKMT2AHSD17B10
SCHEMBL2980266 0.77 KMT2A (0.39) CYP3A4ALDH1A1TSHRKMT2AHPGD
SCHEMBL120227 0.77 KMT2A (0.39) CYP3A4ALDH1A1TSHRKMT2AHPGD
SCHEMBL8919294 0.77 LMNA (0.44) CYP3A4ALDH1A1KMT2ACYP2D6CYP1A2
SCHEMBL10947140 0.76 ALDH1A1 (0.50) CYP3A4ALDH1A1PABPC1APOBEC3AAPOBEC3G
SCHEMBL6372424 0.76 ALDH1A1 (0.54) CYP3A4ALDH1A1PABPC1APOBEC3AAPOBEC3G
SCHEMBL26284298 0.76 ALDH1A1 (0.54) CYP3A4ALDH1A1PABPC1APOBEC3AAPOBEC3G

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1265849-A2 COMPOUNDS AND METHODS TO TREAT ALZHEIMER'S DISEASE Elan Pharmaceuticals, Inc. (US) 2002-12-18 EP claimed
WO-2001070672-A2 COMPOUNDS AND METHODS TO TREAT ALZHEIMER'S DISEASE ELAN PHARMACEUTICALS, INC. (US) 2001-09-27 WO claimed
EP-2282753-A1 ASSAY FOR PATHOGENIC CONFORMERS Novartis AG (CH) 2011-02-16 EP disclosed
EP-2146632-A1 COMPOSITIONS AND METHODS FOR CELLULAR IMAGING AND THERAPY The Board of Regents of The University of Texas System (US) 2010-01-27 EP disclosed
WO-2009134942-A1 ASSAY FOR PATHOGENIC CONFORMERS NOVARTIS AG. (CH) 2009-11-05 WO disclosed
WO-2008130439-A1 COMPOSITIONS AND METHODS FOR CELLULAR IMAGING AND THERAPY THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) 2008-10-30 WO disclosed
WO-2007047305-A1 METHODS OF TREATING AMYLOIDOSIS USING CYCLOPROPYL DERIVATIVE ASPARTYL PROTEASE INHIBITORS ELAN PHARMACEUTICALS, INC. (US) 2007-04-26 WO disclosed
EP-1773758-A1 OXIME DERIVATIVE HYDROXYETHYLAMINE ASPARTYL-PROTEASE INHIBITORS Elan Pharmaceuticals, Inc. (US) 2007-04-18 EP disclosed
WO-2006010094-A1 OXIME DERIVATIVE HYDROXYETHYLAMINE ASPARTYL-PROTEASE INHIBITORS ELAN PHARMACEUTICALS, INC. (US) 2006-01-26 WO disclosed
EP-1353898-A2 COMPOUNDS TO TREAT ALZHEIMER'S DISEASE Elan Pharmaceuticals, Inc. (US) 2003-10-22 EP disclosed
EP-1265849-A2 COMPOUNDS AND METHODS TO TREAT ALZHEIMER'S DISEASE Elan Pharmaceuticals, Inc. (US) 2002-12-18 EP disclosed
WO-2002002512-A2 COMPOUNDS TO TREAT ALZHEIMER'S DISEASE ELAN PHARMACEUTICALS, INC. (US) 2002-01-10 WO disclosed
WO-2001070672-A2 COMPOUNDS AND METHODS TO TREAT ALZHEIMER'S DISEASE ELAN PHARMACEUTICALS, INC. (US) 2001-09-27 WO disclosed